Virpax Pharmaceuticals Inc - VRPX STOCK NEWS

Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research to evaluate Probudur, an injectable long-acting liposomal bupivacaine aimed at reducing postoperative opioid use. Probudur has demonstrated pain control for at least 96 hours in pre-clinical trials. This collaboration aligns with Virpax's strategy for non-dilutive funding and builds on prior partnership with the National Institutes of Health for another pain management product, Envelta.

Virpax Pharmaceuticals (NASDAQ: VRPX) has reported promising preclinical pharmacokinetics results for VRP324, a nasal CBD candidate designed for seizure management in children and adults. The study indicates effective nose-to-brain delivery, achieving higher CBD concentrations in the brain compared to plasma. This method may lead to reduced side effects and drug interactions. The company is preparing a pre-IND application for FDA review, targeting seizures related to disorders like Lennox-Gastaut syndrome and Dravet syndrome.

Virpax Pharmaceuticals (NASDAQ:VRPX) reported its financial results for the year ended December 31, 2021, highlighting significant advancements in its pre-clinical pipeline. The company has selected a clinical trial organization to initiate a First in Human study of Epoladerm for osteoarthritis knee pain in 2022. Virpax received multiple contracts from NCATS for its Envelta and has seen positive preclinical results for both Epoladerm and Envelta. However, operating expenses rose by 147% to $7.2 million, primarily due to increased legal and insurance costs. Cash reserves at year-end stood at approximately $36.8 million.

Virpax Pharmaceuticals has completed all FDA-required pre-clinical studies for its investigational topical analgesic, Epoladerm™, aimed at managing chronic knee pain due to osteoarthritis. The studies encompassed dermal toxicity and phototoxicity, among others. Virpax is preparing to submit its Investigational New Drug Application (IND) including these results. A clinical trial agreement with Altasciences is in place for a first-in-human pilot study in Canada, with patient enrollment expected in 2022.

Management expresses confidence that Epoladerm will be a more effective treatment option for osteoarthritis pain.

Nanomerics Ltd announced a milestone payment following the expansion of its anti-viral spray license for AnQlar™ to Virpax Pharmaceuticals (NASDAQ:VRPX). The agreement now includes worldwide rights, and the deal features an upfront payment with future revenue sharing. This funding will support Nanomerics' growth and clinical programs. CEO expressed satisfaction with the partnership aimed at developing AnQlar™ as a nasal spray to combat respiratory viruses, including SARS-CoV-2 variants.

Virpax Pharmaceuticals (NASDAQ: VRPX) has expanded its exclusive licensing agreement for AnQlar™ with Nanomerics Ltd., securing worldwide rights for development and commercialization. AnQlar has shown antiviral activity against SARS-CoV-2 and influenza in preclinical studies, inhibiting viral replication without adverse effects. Virpax aims for Investigational New Drug (IND) studies completion by Q4 2022 and plans to pursue a nonprescription drug approval pathway. Enhanced global rights are expected to strengthen strategic opportunities for AnQlar.

Virpax Pharmaceuticals (NASDAQ: VRPX) has gained media attention for its potential solutions to the opioid epidemic and COVID-19. The focus is on several non-addictive drug candidates: AnQlar™, an intranasal antiviral; Epoladerm™, targeting osteoarthritis pain; Probudur™, a long-acting anesthetic for post-surgical pain; and Envelta™, for cancer-related pain. CEO Anthony Mack shared insights on the opioid crisis, while Dr. Sheila Mathias, Chief Scientific Officer, discussed the company's product portfolio in interviews.

Virpax Pharmaceuticals (NASDAQ: VRPX) reported promising preclinical data on Envelta (NES100), an intranasal enkephalin spray designed for pain management in acute and chronic cases. Studies indicate Envelta is well-tolerated with no adverse findings in toxicity assessments conducted by the NIH. The company is focused on submitting an IND to the FDA to initiate Phase 1 trials, aiming to support its potential as a non-addictive treatment for cancer pain and PTSD.

Virpax Pharmaceuticals (NASDAQ: VRPX) has selected Altasciences to conduct a first-in-human study of Epoladerm™ for chronic knee pain due to osteoarthritis. This innovative treatment utilizes a pre-filled device for a convenient topical spray application. Set to begin in Q2 2022 at Altasciences’ Montreal facility, the study aims to support the FDA's 505(b)(2) approval pathway. Altasciences, experienced in clinical trials, is committed to advancing this analgesic therapy towards regulatory approval, enhancing patient care through its cutting-edge technology.